<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">biopreparat</journal-id><journal-title-group><journal-title xml:lang="ru">БИОпрепараты. Профилактика, диагностика, лечение</journal-title><trans-title-group xml:lang="en"><trans-title>Biological Products. Prevention, Diagnosis, Treatment</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2221-996X</issn><issn pub-type="epub">2619-1156</issn><publisher><publisher-name>Scientific Centre for Expert Evaluation of Medicinal Products</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">biopreparat-81</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Исследование остаточной вирулентности и иммунизирующей способности посевных серий Mycobacterium bovis BCG-1</article-title><trans-title-group xml:lang="en"><trans-title>Determination of residual virulence and immunogenicity of Mycobacterium bovis BCG-1 seed lots</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Леви</surname><given-names>Д. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Levi</surname><given-names>D. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Главный эксперт управления экспертизы противобактериальных МИБП Центра экспертизы и контроля МИБП, д-р мед. наук, профессор</p></bio><bio xml:lang="en"><p>Chief expert of the Division for Expert Evaluation of Antibacterial Medicinal Immunobiological Products of the Centre for Evaluation and Control of Medicinal Immunobiological Products. Doctor of Medical Sciences, professor,</p><p>Petrovsky boulevard 8, bld. 2, Moscow 127051</p></bio><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Александрова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Aleksandrova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>главный эксперт лаборатории бактериальных вакцин Испытательного центра экспертизы качества МИБП, канд. мед. наук</p></bio><bio xml:lang="en"><p>Chief expert of the Laboratory of Bacterial Vaccines of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality. Candidate of Medical Sciences,</p><p>Petrovsky boulevard 8, bld. 2, Moscow 127051</p></bio><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Обухов</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Obukhov</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>начальник управления экспертизы противобактериальных МИБП Центра экспертизы и контроля МИБП</p></bio><bio xml:lang="en"><p>Head of the Division for Expert Evaluation of Antibacterial Medicinal Immunobiological Products of the Centre for Evaluation and Control of Medicinal Immunobiological Products,</p><p>Petrovsky boulevard 8, bld. 2, Moscow 127051</p></bio><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научный центр экспертизы средств медицинского применения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2018</year></pub-date><volume>17</volume><issue>1</issue><fpage>48</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Леви Д.Т., Александрова Н.В., Обухов Ю.И., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Леви Д.Т., Александрова Н.В., Обухов Ю.И.</copyright-holder><copyright-holder xml:lang="en">Levi D.T., Aleksandrova N.V., Obukhov Y.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.biopreparations.ru/jour/article/view/81">https://www.biopreparations.ru/jour/article/view/81</self-uri><abstract><p>Статья посвящена актуальной на сегодняшний день проблеме стабильности системы посевных серий, используемой в стране при производстве вакцин БЦЖ с 1947 г. Данная проблема недостаточно изучена и требует дальнейшего исследования. В ранее проведенной авторами работе использование инновационных (молекулярно-генетических) методов позволило подтвердить соответствие посевных серий БЦЖ-1, применявшихся в стране с 1947 г., международному референс-реагенту (BCG Vaccine of Russian BCG-I sub-strain-International Reference Reagent) по показателю «Подлинность». Настоящая статья включает результаты дальнейшего сравнительного испытания посевных серий БЦЖ-1 367 «щ» (1982) и 368 «щ» (2006). В рамках исследовательской задачи авторы уделили особое внимание таким характеристикам качества, как специфическая активность, остаточная вирулентность (приживаемость), специфическая безопасность (отсутствие вирулентных микобактерий туберкулеза), сенсибилизирующее действие (по индукции иммуноопосредованной гиперчувствительности замедленного типа к туберкулину) и протективные свойства. Полученные результаты оценки этих серий были близки по своим значениям и не отличались от результатов, полученных при аттестации, проведенной непосредственно после изготовления каждого посевного материала. Эти результаты свидетельствуют о высокой стабильности биологических свойств посевных серий. В статье также представлены данные литературы по исследуемой теме.</p></abstract><trans-abstract xml:lang="en"><p>The article is devoted to a challenging issue of stability of seed lot systems that have been used in Russia since 1947 to produce BCG vaccines. This problem is underexplored and needs further investigation. In an earlier study the authors of the article used innovative (molecular genetic) methods to demonstrate the conformity of BCG-1 seed lots used in Russia to the international reference reagent ( BCG Vaccine of Russian BCG-I sub-strain-International Reference Reagent ) in terms of «Identification». This article lays out the results of new comparative studies of BCG-1 367 «shch» (1982) and 368 «shch» (2006). During the study special emphasis was put on such quality parameters as residual virulence (survival), specific safety (absence of virulent mycobacteria tuberculosis), sensitization effect (by induction of immune-mediated delayed hypersensitivity to tuberculin), and protective effects. The values obtained in the batches evaluation were very close and did not differ from the results obtained during certification performed just after the production of each seed lot. These results testify to the high degree of stability of the seed lots biological properties. The article also cites literary sources that address the issue in question.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вакцина БЦЖ</kwd><kwd>субштаммы БЦЖ</kwd><kwd>система посевных серий</kwd><kwd>остаточная вирулентность</kwd><kwd>приживаемость</kwd><kwd>BCG vaccine</kwd><kwd>BCG substrains</kwd><kwd>seed lot system</kwd><kwd>residual virulence</kwd><kwd>survival</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Аксенова ВА, Леви ДТ. Туберкулезные вакцины / Вакцины и вакцинация. Национальное руководство. Зверев ВВ, Семенов БФ, Хаитов РМ, ред. М.: «ГЭОТАР-Медиа», 2011. С. 371-411.</mixed-citation><mixed-citation xml:lang="en">Aksenova VA, Levi DT. TB vaccines/Vaccines and vaccination. Nacional manual. Zverev VV, Semenov BF, Haitov RM, eds. Moscow: GEOTAR-Media, 2011. P. 371–411 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014; 349: g4643.</mixed-citation><mixed-citation xml:lang="en">Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ. 2014; 349: g4643.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359(9315): 1393-401.</mixed-citation><mixed-citation xml:lang="en">Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359(9315): 1393–401.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мушкин АЮ. БЦЖ-оститы. Диагностика, критерии постановки и лечение. Проблемы туберкулеза и болезней легких. 2004; (1): 21-3.</mixed-citation><mixed-citation xml:lang="en">Mushkin AYu. BCG osteitis: diagnosis and treatment. Problems of Tuberculosis and Lung Diseases 2004; (1): 21–3 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Recommendations to assure the quality, safety and efficacy of BCG vaccines (Annex 3). WHO Technical Report Series No. 979, 2013.</mixed-citation><mixed-citation xml:lang="en">Recommendations to assure the quality, safety and efficacy of BCG vaccines (Annex 3). WHO Technical Report Series No. 979, 2013.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Леви ДТ, Обухов ЮИ, Александрова НВ, Волкова РА, Эльберт ЕВ, Альварес Фигероа МВ и др. Оценка подлинности и стабильности вакцины БЦЖ методом мультиплексной ПЦР. БИОпрепараты. Профилактика, диагностика, лечение 2016; 16(1): 49-54.</mixed-citation><mixed-citation xml:lang="en">Levi DT, Obukhov YuI, Aleksandrova NV, Volkova RA, Elbert EV, Alvarez Figeroa MV, et al. Identity and stability assessment of BCG vaccine by multiplex PCR. BIOpreparations. Prevention, Diagnosis, Treatment 2016; 16(1): 49–54 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Гланц С. Медико-биологическая статистика. М.: Практика; 1999.</mixed-citation><mixed-citation xml:lang="en">Glantz SA. Primer of Biostatistics. Moscow: Praktika; 1999 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">ФС. 3.3.1.0018.15. Вакцина туберкулезная БЦЖ живая. Государственная фармакопея Российской Федерации. 13-е изд. Т. 3. М.; 2015. С. 917-22. Available from: http://femb.ru/feml.</mixed-citation><mixed-citation xml:lang="en">ФС. 3.3.1.0018.15. Mycobacterium bovis BCG vaccine (monograph). The State Pharmacopoeia of the Russian Federation. 13th edition. V. 3. Moscow; 2015. P. 917–22. Available from: http://femb.ru/feml (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine 1999; 17(7-8): 915-22.</mixed-citation><mixed-citation xml:lang="en">Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine 1999; 17(7–8): 915–22.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Behr MA. Correlation between BCG genomics and protective efficacy. Scand J Infect Dis. 2001; 33(4): 249-52.</mixed-citation><mixed-citation xml:lang="en">Behr MA. Correlation between BCG genomics and protective efficacy. Scand J Infect Dis. 2001; 33(4): 249–52.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Corbel MJ, Fruth U, Griffiths E, Knezevic I. Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15-16 December 2003. Vaccine 2004; 22(21-22): 2675-80.</mixed-citation><mixed-citation xml:lang="en">Corbel MJ, Fruth U, Griffiths E, Knezevic I. Report on a WHO consultation on the characterisation of BCG strains, Imperial College, London 15–16 December 2003. Vaccine 2004; 22(21–22): 2675–80.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Seki M, Honda I, Fujita I, Yano I, Yamamoto S, Koyama A. Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains. Vaccine 2009; 27(11): 1710-6.</mixed-citation><mixed-citation xml:lang="en">Seki M, Honda I, Fujita I, Yano I, Yamamoto S, Koyama A. Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains. Vaccine 2009; 27(11): 1710–6.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
